This petition is designed to educate the politicians in Washinginton D.C., Attorney General Jeff Sessions | jeff.sessions@usdoj.gov, Demetra Ashley, Acting Assistant Administrator of the DEA (DC) 202 307-7165 | Demetra.Ashley@usdoj.gov, the United Nations (NY office), Elizabeth H. Curda the Director of Strategic Issues at the Office of Government Accountability, and President Donald Trump on the Accepted Medical Use of Cannabis and all of the extracts that the plant produces.
On December 14th 2016 the DEA made a decision to include all of the Cannabis plant genus’ extracts as a Schedule 1 Narcotic that will take effect on January 17th, 2017.
On January 4th, 2018, Attorney General Jeff Sessions directs all U.S. Attorneys to enforce the laws enacted by Congress and to follow well-established principles when pursuing prosecutions related to marijuana activities.
On January 5th, 2018 the letter to the decision makers was updated to include the following words:
“Petition to have Attorney General Jeff Sessions conduct an Attorney General hearing on the Scheduling and classification of Cannabis Sativa according to Title 21 United States Code (USC) Controlled Substances Act
SUBCHAPTER I — CONTROL AND ENFORCEMENT
Part B — Authority to Control; Standards and Schedules
§811. Authority and criteria for classification of substances
(a) Rules and regulations of Attorney General; hearing.”
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA–342]
RIN 1117–AB33
Establishment of a New Drug Code for Marihuana Extract
“Consistent with the Controlled Substances Act (CSA), the schedules contained in DEA regulations include marihuana (drug code 7360) in Schedule I. 21 CFR 1308.11(d)(23). This listing includes (unless specifically excepted or unless listed in another schedule) any material, compound, mixture, or preparation, which contains any quantity of the substance, or which contains any of its salts, isomers, and salts of isomers that are possible within the specific chemical designation. Because the definition of marihuana in 21 U.S.C. 802(16) includes both derivatives and preparations of marihuana, the DEA until now has used drug code 7360 for extracts of marihuana.” – 90194 Federal Register / Vol. 81, No. 240 / Wednesday, December 14, 2016 / Rules and Regulations
“Executive Order 13132, Federalism – This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The rule does not have substantial direct effects on the States, on the relationship between the national government and the States, or the distribution of power and responsibilities among the various levels of government.” *This is taken from the above document and is false in itself and should be challenged on this statement as to the validity of the information contained there in.
From the Drug Enforcement Agencies website. “Drug Schedules
Drugs, substances, and certain chemicals used to make drugs are classified into five (5) distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug; for example, Schedule I drugs have a high potential for abuse and the potential to create severe psychological and/or physical dependence. As the drug schedule changes– Schedule II, Schedule III, etc., so does the abuse potential– Schedule V drugs represents the least potential for abuse. A Listing of drugs and their schedule are located at Controlled Substance Act (CSA) Scheduling or CSA Scheduling by Alphabetical Order.These lists describes the basic or parent chemical and do not necessarily describe the salts, isomers and salts of isomers, esters, ethers and derivatives which may also be classified as controlled substances. These lists are intended as general references and are not comprehensive listings of all controlled substances.
Please note that a substance need not be listed as a controlled substance to be treated as a Schedule I substance for criminal prosecution. A controlled substance analogue is a substance which is intended for human consumption and is structurally or pharmacologically substantially similar to or is represented as being similar to a Schedule I or Schedule II substance and is not an approved medication in the United States. (See 21 U.S.C. §802(32)(A) for the definition of a controlled substance analogue and 21 U.S.C. §813 for the schedule.)
Schedule I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are:
heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
*However since Cannabis does have several accepted Medical uses, this classification is false as well.
There are over 380,000 articles written and listed in Google Scholar showing that Science has proven that there is not only accepted medical uses, but that there are thousands of Industrial applications as well. The medical value alone would save our economy Billions of dollars in Tax burden that is wasted daily in the medical industry on substances that harm our bodies and create a cascade of harmful side effects, where as Cannabis has shown to replace these chemicals in treating the following conditions including (but not limited to) :
1. Neurodegenerative diseases,
2. Alzheimer’s
3. Strokes
4. Glutamate toxicity
5. Multiple Sclerosis (MS)
6. Parkinson’s disease
7. Neurodegeneration caused by alcohol abuse
8. Central and peripheral neuropathic pain
9. Rheumatoid arthritis
10. Cancer pain
11. “….randomized clinical trial reporting clinical improvement in patients with schizophrenia treated with CBD.”
12. “CBD reduced anxiety in patients with social anxiety subjected to a stressful public speaking task.”
13. “CBD reduced the rewarding effects of morphine…..”
14. “……there are also several pre-clinical reports showing anti-tumor effects of CBD in cell culture and in animal models.xxviii These studies have found reduced cell viability, increased cancer cell death, decreased tumor growth, and inhibition of metastasis (reviewed in McAllister et al, 2015).xxix These effects may be due to the antioxidant and anti-inflammatory effects of CBD;xxx however these findings have not yet been explored in human patients.” – The Biology and Potential Therapeutic Effects of Cannabidiol (National Institute on Drug Abuse)
There have been ZERO reported overdoses or deaths caused by Cannabis toxicity.
Every human has an endocannabinoid system that can be delivered through the mothers breast milk. Most humans are cannabinoid deficient and since modern medicine does not test for this deficiency then most of us would never know we need it for proper digestion and proper oxygenation of our bloodstream that allows the body to heal itself with a proper diet.
“During the last few years, the endocannabinoid system has emerged as a highly relevant topic in the scientific community. Many different regulatory actions have been attributed to endocannabinoids, and their involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid receptors, named CB1 receptor and CB2 receptor, first discovered as the molecular targets of the psychotropic component of the plant Cannabis sativa, participate in the physiological modulation of many central and peripheral functions. CB2 receptor is mainly expressed in immune cells, whereas CB1 receptor is the most abundant G protein-coupled receptor expressed in the brain. CB1 receptor is expressed in the hypothalamus and the pituitary gland, and its activation is known to modulate all the endocrine hypothalamic-peripheral endocrine axes. An increasing amount of data highlights the role of the system in the stress response by influencing the hypothalamic-pituitary-adrenal axis and in the control of reproduction by modifying gonadotropin release, fertility, and sexual behavior.
The ability of the endocannabinoid system to control appetite, food intake, and energy balance has recently received great attention, particularly in the light of the different modes of action underlying these functions. The endocannabinoid system modulates rewarding properties of food by acting at specific mesolimbic areas in the brain. In the hypothalamus, CB1 receptor and endocannabinoids are integrated components of the networks controlling appetite and food intake. Interestingly, the endocannabinoid system was recently shown to control metabolic functions by acting on peripheral tissues, such as adipocytes, hepatocytes, the gastrointestinal tract, and, possibly, skeletal muscle. The relevance of the system is further strenghtened by the notion that drugs interfering with the activity of the endocannabinoid system are considered as promising candidates for the treatment of various diseases, including obesity.”- The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
The above is just one reference in over 380,000 Medical Journal entries where Science and Medical Doctors have concluded that there is Accepted Medical Use of the Cannabis plant. This petition is designed to educate the politicians in Washinginton D.C., Attorney General Jeff Sessions | jeff.sessions@usdoj.gov, Demetra Ashley, Acting Assistant Administrator of the DEA (DC) 202 307-7165 | Demetra.Ashley@usdoj.gov, the United Nations (NY office), Elizabeth H. Curda the Director of Strategic Issues at the Office of Government Accountability, and President Donald Trump on the Accepted Medical Use of Cannabis and all of the extracts that the plant produces.
Please Contact you local Congressperson or Senator with a copy of this petition and ask them if they have had their Endocannabinoid System tested recently and if not, ask them why their Doctors are not testing for such a crucial deficiency?
Please sign this Petition to have Attorney General Jeff Sessions conduct an Attorney General hearing on the Scheduling and classification of Cannabis Sativa according to Title 21 United States Code (USC) Controlled Substances Act
SUBCHAPTER I — CONTROL AND ENFORCEMENT
Part B — Authority to Control; Standards and Schedules
§811. Authority and criteria for classification of substances
(a) Rules and regulations of Attorney General; hearing.
Thank you for your time and efforts to educate others in this matter.